Symbols / OTLK Stock $1.10 +23.60% Outlook Therapeutics, Inc.
OTLK (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Ratings
Current target
$1.10
Low
$0.50
High
$10.00
Mean
$5.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-06-11 | main | Ascendiant Capital | Buy → Buy | $10 |
| 2026-05-18 | down | BTIG | Buy → Neutral | — |
| 2026-03-11 | main | Ascendiant Capital | Buy → Buy | $6 |
| 2026-02-18 | reit | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2026-02-18 | main | Chardan Capital | Neutral → Neutral | $1 |
| 2026-01-05 | main | Chardan Capital | Neutral → Neutral | $1 |
| 2026-01-02 | main | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2025-12-22 | main | Ascendiant Capital | Buy → Buy | $10 |
| 2025-09-30 | reit | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2025-09-22 | main | Ascendiant Capital | Buy → Buy | $8 |
| 2025-08-29 | down | Guggenheim | Buy → Neutral | — |
| 2025-08-29 | down | HC Wainwright & Co. | Buy → Neutral | $1 |
| 2025-08-28 | main | Chardan Capital | Neutral → Neutral | $3 |
| 2025-08-15 | main | Chardan Capital | Neutral → Neutral | $3 |
| 2025-06-06 | main | Ascendiant Capital | Buy → Buy | $21 |
| 2025-02-24 | main | Ascendiant Capital | Buy → Buy | $24 |
| 2025-02-18 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-02-18 | main | Chardan Capital | Neutral → Neutral | $3 |
| 2025-01-17 | reit | Guggenheim | Buy → Buy | $12 |
| 2025-01-17 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
- Outlook Therapeutics (OTLK) Stock After FDA Class 1 BLA Resubmission Is The Valuation Out Of Line - simplywall.st Fri, 12 Jun 2026 07
- OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits hu, 11 Jun 2026 21
- Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity (NASDAQ:OTLK) - Seeking Alpha Sat, 06 Jun 2026 12
- US Stock Market Outlook: Returning to Balance of Growth and Value Stocks - Morningstar Mon, 08 Jun 2026 09
- FDA cites substantial evidence for LYTENAVA in macular degeneration - Stock Titan ue, 26 May 2026 07
- $OTLK stock is down 7% today. Here's what we see in our data. - Quiver Quantitative Fri, 05 Jun 2026 19
- Why I'm Rethinking My Bearish Outlook on SoundHound AI: The Stock Could Be a Long-Term Winner - The Motley Fool hu, 11 Jun 2026 02
- OTLK Stock Rocket Nearly 140%: FDA's Lytenava FDR Approval Pushes Stock On Track For Best Week On Record - Stocktwits Mon, 01 Jun 2026 07
- After an FDA dispute meeting, Outlook awaits May feedback on eye drug - Stock Titan ue, 21 Apr 2026 07
- Why RDW, TE, OTLK Stocks Posted Double-Digit Gains On Tuesday - Yahoo Finance ue, 26 May 2026 07
- Eye drug LYTENAVA back at FDA, 60-day review window - Stock Titan Mon, 01 Jun 2026 07
- $OTLK stock is down 4% today. Here's what we see in our data. - Quiver Quantitative Fri, 29 May 2026 14
- Outlook Therapeutics (NASDAQ: OTLK) amends warrants and sells 8.54M shares - Stock Titan Fri, 29 May 2026 07
- Director at Outlook Therapeutics (OTLK) buys 34K shares at $0.44 - Stock Titan Wed, 27 May 2026 07
- Director at Outlook Therapeutics (NASDAQ: OTLK) buys 29,000 shares - Stock Titan Wed, 03 Jun 2026 22
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
1.41
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
1.41
|
0.00
|
0.00
|
0.00
|
| Cost Of Revenue |
|
1.36
|
0.00
|
—
|
—
|
| Reconciled Cost Of Revenue |
|
1.36
|
0.00
|
—
|
—
|
| Gross Profit |
|
0.06
|
0.00
|
—
|
—
|
| Operating Expense |
|
67.12
-6.39%
|
71.70
+34.97%
|
53.13
-15.77%
|
63.07
|
| Research And Development |
|
27.18
-34.92%
|
41.76
+57.88%
|
26.45
-37.51%
|
42.33
|
| Selling General And Administration |
|
39.94
+33.39%
|
29.94
+12.25%
|
26.67
+28.61%
|
20.74
|
| General And Administrative Expense |
|
39.94
+33.39%
|
29.94
+12.25%
|
26.67
+28.61%
|
20.74
|
| Salaries And Wages |
|
16.66
+53.03%
|
10.89
+21.94%
|
8.93
-2.14%
|
9.12
|
| Other Gand A |
|
23.28
+22.18%
|
19.05
+7.37%
|
17.75
+52.76%
|
11.62
|
| Total Expenses |
|
68.48
-4.50%
|
71.70
+34.97%
|
53.13
-15.77%
|
63.07
|
| Operating Income |
|
-67.06
+6.47%
|
-71.70
-34.97%
|
-53.13
+15.77%
|
-63.07
|
| Total Operating Income As Reported |
|
-67.06
+6.47%
|
-71.70
-34.97%
|
-53.13
+15.77%
|
-63.07
|
| EBITDA |
|
-63.58
+11.81%
|
-72.09
-27.81%
|
-56.40
+12.36%
|
-64.36
|
| Normalized EBITDA |
|
-106.59
+3.74%
|
-110.73
-98.17%
|
-55.88
+12.41%
|
-63.80
|
| Reconciled Depreciation |
|
0.12
+2.80%
|
0.11
+157.67%
|
0.04
-78.41%
|
0.20
|
| EBIT |
|
-63.69
+11.79%
|
-72.21
-27.92%
|
-56.45
+12.57%
|
-64.56
|
| Total Unusual Items |
|
43.02
+11.33%
|
38.64
+7435.32%
|
-0.53
+5.88%
|
-0.56
|
| Total Unusual Items Excluding Goodwill |
|
43.02
+11.33%
|
38.64
+7435.32%
|
-0.53
+5.88%
|
-0.56
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-0.58
+43.67%
|
-1.03
|
| Other Special Charges |
|
—
|
—
|
0.58
-43.67%
|
1.03
|
| Impairment Of Capital Assets |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-62.42
+17.17%
|
-75.37
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Pretax Income |
|
-63.98
+15.11%
|
-75.36
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Net Non Operating Interest Income Expense |
|
-0.19
+91.41%
|
-2.25
-44.31%
|
-1.56
-4.86%
|
-1.49
|
| Interest Expense Non Operating |
|
0.28
-91.03%
|
3.16
+24.72%
|
2.53
+70.17%
|
1.49
|
| Net Interest Income |
|
-0.19
+91.41%
|
-2.25
-44.31%
|
-1.56
-4.86%
|
-1.49
|
| Interest Expense |
|
0.28
-91.03%
|
3.16
+24.72%
|
2.53
+70.17%
|
1.49
|
| Interest Income Non Operating |
|
0.09
-90.10%
|
0.91
-6.72%
|
0.97
|
—
|
| Interest Income |
|
0.09
-90.10%
|
0.91
-6.72%
|
0.97
|
—
|
| Other Income Expense |
|
3.28
+332.53%
|
-1.41
+67.16%
|
-4.29
-187.93%
|
-1.49
|
| Other Non Operating Income Expenses |
|
-39.60
+0.88%
|
-39.95
-963.56%
|
-3.76
-325.41%
|
-0.88
|
| Gain On Sale Of Security |
|
43.02
+11.33%
|
38.64
+75781.38%
|
0.05
-89.07%
|
0.47
|
| Tax Provision |
|
-1.55
-55522.46%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
1.03
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-62.42
+17.17%
|
-75.37
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Net Income From Continuing Operation Net Minority Interest |
|
-62.42
+17.17%
|
-75.37
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Net Income From Continuing And Discontinued Operation |
|
-62.42
+17.17%
|
-75.37
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Net Income Continuous Operations |
|
-62.42
+17.17%
|
-75.37
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Normalized Income |
|
-104.41
+8.42%
|
-114.00
-95.03%
|
-58.46
+10.74%
|
-65.49
|
| Net Income Common Stockholders |
|
-62.42
+17.17%
|
-75.37
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
—
|
| Diluted EPS |
|
-1.79
+55.91%
|
-4.06
+15.42%
|
-4.80
+22.58%
|
-6.20
|
| Basic EPS |
|
-1.79
+55.91%
|
-4.06
+15.42%
|
-4.80
+22.58%
|
-6.20
|
| Basic Average Shares |
|
34.80
+87.59%
|
18.55
+48.29%
|
12.51
+17.96%
|
10.60
|
| Diluted Average Shares |
|
34.80
+87.59%
|
18.55
+48.29%
|
12.51
+17.96%
|
10.60
|
| Diluted NI Availto Com Stockholders |
|
-62.42
+17.17%
|
-75.37
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Earnings From Equity Interest |
|
-0.14
-39.97%
|
-0.10
-816.00%
|
-0.01
+77.43%
|
-0.05
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Assets |
|
18.58
-35.52%
|
28.82
-10.77%
|
32.30
+13.23%
|
28.53
|
| Current Assets |
|
17.39
-36.57%
|
27.42
-11.50%
|
30.98
+12.57%
|
27.52
|
| Cash Cash Equivalents And Short Term Investments |
|
8.08
-45.85%
|
14.93
-36.19%
|
23.39
+34.46%
|
17.40
|
| Cash And Cash Equivalents |
|
8.08
-45.85%
|
14.93
-36.19%
|
23.39
+34.46%
|
17.40
|
| Receivables |
|
1.49
|
0.00
|
—
|
—
|
| Accounts Receivable |
|
1.49
|
0.00
|
—
|
—
|
| Inventory |
|
3.34
|
0.00
|
—
|
—
|
| Raw Materials |
|
2.35
|
—
|
—
|
—
|
| Work In Process |
|
0.96
|
—
|
—
|
—
|
| Finished Goods |
|
0.03
|
—
|
—
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
10.12
|
| Other Current Assets |
|
4.48
-64.15%
|
12.49
+64.60%
|
7.59
-25.05%
|
10.12
|
| Total Non Current Assets |
|
1.20
-15.06%
|
1.41
+6.49%
|
1.32
+31.18%
|
1.01
|
| Net PPE |
|
0.23
-17.89%
|
0.27
+949.38%
|
0.03
-62.80%
|
0.07
|
| Gross PPE |
|
0.23
-17.89%
|
0.27
+949.38%
|
0.03
-62.80%
|
0.07
|
| Accumulated Depreciation |
|
—
|
—
|
—
|
-1.07
|
| Other Properties |
|
0.23
-17.89%
|
0.27
+949.38%
|
0.03
-62.80%
|
0.07
|
| Investments And Advances |
|
0.55
-20.34%
|
0.69
-12.69%
|
0.79
-1.37%
|
0.80
|
| Long Term Equity Investment |
|
0.55
-20.34%
|
0.69
-12.69%
|
0.79
-1.37%
|
0.80
|
| Other Non Current Assets |
|
0.42
-4.95%
|
0.44
-12.37%
|
0.50
+279.73%
|
0.13
|
| Total Liabilities Net Minority Interest |
|
50.77
-50.17%
|
101.90
+118.02%
|
46.74
+136.16%
|
19.79
|
| Current Liabilities |
|
45.81
+7.66%
|
42.55
-8.94%
|
46.73
+136.86%
|
19.73
|
| Payables And Accrued Expenses |
|
12.78
+6.07%
|
12.05
+17.48%
|
10.26
+50.84%
|
6.80
|
| Payables |
|
10.49
+6.81%
|
9.83
+16.54%
|
8.43
+57.65%
|
5.35
|
| Accounts Payable |
|
10.19
+27.90%
|
7.97
+21.21%
|
6.57
+88.30%
|
3.49
|
| Current Accrued Expenses |
|
2.29
+2.78%
|
2.22
+21.84%
|
1.83
+25.77%
|
1.45
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
3.03
+198.91%
|
1.01
+10.11%
|
0.92
-53.45%
|
1.98
|
| Total Tax Payable |
|
0.30
-83.73%
|
1.86
+0.00%
|
1.86
+0.00%
|
1.86
|
| Income Tax Payable |
|
0.30
-83.73%
|
1.86
+0.00%
|
1.86
+0.00%
|
1.86
|
| Current Debt And Capital Lease Obligation |
|
30.01
+1.75%
|
29.49
-17.06%
|
35.56
+224.59%
|
10.95
|
| Current Debt |
|
29.95
+1.72%
|
29.44
-17.19%
|
35.55
+225.71%
|
10.92
|
| Other Current Borrowings |
|
29.95
+1.72%
|
29.44
-17.19%
|
35.55
+225.71%
|
10.92
|
| Current Capital Lease Obligation |
|
0.06
+15.70%
|
0.05
+1093.04%
|
0.00
-88.99%
|
0.04
|
| Total Non Current Liabilities Net Minority Interest |
|
4.96
-91.65%
|
59.35
+954168.13%
|
0.01
-89.87%
|
0.06
|
| Long Term Debt And Capital Lease Obligation |
|
0.19
-23.54%
|
0.25
|
0.00
-100.00%
|
0.00
|
| Long Term Debt |
|
—
|
—
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
0.19
-23.54%
|
0.25
|
0.00
-100.00%
|
0.00
|
| Stockholders Equity |
|
-32.19
+55.95%
|
-73.08
-406.15%
|
-14.44
-265.26%
|
8.74
|
| Common Stock Equity |
|
-32.19
+55.95%
|
-73.08
-406.15%
|
-14.44
-265.26%
|
8.74
|
| Capital Stock |
|
0.54
+125.42%
|
0.24
+83.71%
|
0.13
-94.28%
|
2.27
|
| Common Stock |
|
0.54
+125.42%
|
0.24
+83.71%
|
0.13
-94.28%
|
2.27
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
53.89
+125.42%
|
23.91
+83.71%
|
13.01
+14.49%
|
11.37
|
| Ordinary Shares Number |
|
53.89
+125.42%
|
23.91
+83.71%
|
13.01
+14.49%
|
11.37
|
| Additional Paid In Capital |
|
572.98
+21.92%
|
469.97
+3.67%
|
453.35
+9.14%
|
415.40
|
| Retained Earnings |
|
-605.71
-11.49%
|
-543.28
-16.11%
|
-467.92
-14.42%
|
-408.94
|
| Total Equity Gross Minority Interest |
|
-32.19
+55.95%
|
-73.08
-406.15%
|
-14.44
-265.26%
|
8.74
|
| Total Capitalization |
|
-32.19
+55.95%
|
-73.08
-406.15%
|
-14.44
-265.26%
|
8.74
|
| Working Capital |
|
-28.43
-87.78%
|
-15.14
+3.91%
|
-15.75
-302.20%
|
7.79
|
| Invested Capital |
|
-2.24
+94.87%
|
-43.64
-306.68%
|
21.11
+7.44%
|
19.65
|
| Total Debt |
|
30.19
+1.54%
|
29.74
-16.36%
|
35.56
+224.47%
|
10.96
|
| Net Debt |
|
21.86
+50.66%
|
14.51
+19.36%
|
12.16
|
—
|
| Capital Lease Obligations |
|
0.25
-16.83%
|
0.30
+6879.82%
|
0.00
-90.08%
|
0.04
|
| Net Tangible Assets |
|
-32.19
+55.95%
|
-73.08
-406.15%
|
-14.44
-265.26%
|
8.74
|
| Tangible Book Value |
|
-32.19
+55.95%
|
-73.08
-406.15%
|
-14.44
-265.26%
|
8.74
|
| Current Notes Payable |
|
—
|
—
|
—
|
—
|
| Derivative Product Liabilities |
|
4.77
-91.93%
|
59.10
+950197.68%
|
0.01
-89.12%
|
0.06
|
| Interest Payable |
|
—
|
—
|
—
|
0.00
|
| Investments In Other Ventures Under Equity Method |
|
—
|
—
|
—
|
—
|
| Investmentsin Joint Venturesat Cost |
|
0.55
-20.34%
|
0.69
-12.69%
|
0.79
-1.37%
|
0.80
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-51.83
+24.66%
|
-68.79
-60.08%
|
-42.97
+24.18%
|
-56.67
|
| Cash Flow From Continuing Operating Activities |
|
-51.83
+24.66%
|
-68.79
-60.08%
|
-42.97
+24.18%
|
-56.67
|
| Net Income From Continuing Operations |
|
-62.42
+17.17%
|
-75.37
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Depreciation Amortization Depletion |
|
0.12
+2.80%
|
0.11
+157.67%
|
0.04
-78.41%
|
0.20
|
| Depreciation And Amortization |
|
0.12
+2.80%
|
0.11
+157.67%
|
0.04
-78.41%
|
0.20
|
| Other Non Cash Items |
|
33.52
+1149.95%
|
2.68
+95.58%
|
1.37
-17.16%
|
1.66
|
| Stock Based Compensation |
|
8.90
+65.23%
|
5.39
-2.92%
|
5.55
-28.06%
|
7.71
|
| Asset Impairment Charge |
|
—
|
—
|
—
|
—
|
| Operating Gains Losses |
|
-42.87
-3993.89%
|
-1.05
-294.76%
|
0.54
-11.61%
|
0.61
|
| Gain Loss On Investment Securities |
|
-43.02
-3646.93%
|
-1.15
-2154.62%
|
-0.05
+89.07%
|
-0.47
|
| Unrealized Gain Loss On Investment Securities |
|
6.07
+147.22%
|
2.46
-34.58%
|
3.76
+325.41%
|
0.88
|
| Change In Working Capital |
|
4.86
+261.00%
|
-3.02
-163.49%
|
4.75
+382.19%
|
-1.68
|
| Change In Receivables |
|
-1.49
|
0.00
|
—
|
—
|
| Changes In Account Receivables |
|
-1.49
|
0.00
|
—
|
—
|
| Change In Inventory |
|
-3.34
|
0.00
|
—
|
—
|
| Change In Prepaid Assets |
|
8.01
+263.47%
|
-4.90
-287.29%
|
2.62
+184.61%
|
-3.09
|
| Change In Payables And Accrued Expense |
|
1.82
-3.41%
|
1.89
-20.47%
|
2.37
+63.40%
|
1.45
|
| Change In Accrued Expense |
|
1.71
+247.79%
|
0.49
+169.10%
|
-0.71
-555.78%
|
0.16
|
| Change In Payable |
|
0.11
-92.01%
|
1.39
-54.78%
|
3.08
+138.05%
|
1.30
|
| Change In Account Payable |
|
1.67
+19.50%
|
1.39
-54.78%
|
3.08
+138.05%
|
1.30
|
| Change In Other Current Assets |
|
-0.10
-1514.36%
|
-0.01
+97.17%
|
-0.21
|
0.00
|
| Change In Other Current Liabilities |
|
-0.05
-1568.83%
|
0.00
+112.64%
|
-0.03
+37.01%
|
-0.04
|
| Investing Cash Flow |
|
—
|
—
|
—
|
—
|
| Cash Flow From Continuing Investing Activities |
|
—
|
—
|
—
|
—
|
| Net Business Purchase And Sale |
|
—
|
—
|
—
|
—
|
| Purchase Of Business |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
44.98
-25.43%
|
60.33
+23.20%
|
48.97
-17.83%
|
59.59
|
| Cash Flow From Continuing Financing Activities |
|
44.98
-25.43%
|
60.33
+23.20%
|
48.97
-17.83%
|
59.59
|
| Net Issuance Payments Of Debt |
|
-3.04
-71205.04%
|
-0.00
-100.02%
|
19.77
+952.41%
|
-2.32
|
| Issuance Of Debt |
|
33.10
|
0.00
-100.00%
|
30.00
+200.00%
|
10.00
|
| Repayment Of Debt |
|
-36.14
-846925.69%
|
-0.00
+99.96%
|
-10.23
+16.94%
|
-12.32
|
| Long Term Debt Issuance |
|
33.10
|
0.00
-100.00%
|
30.00
+200.00%
|
10.00
|
| Long Term Debt Payments |
|
-36.14
-846925.69%
|
-0.00
+99.96%
|
-10.23
+16.94%
|
-12.32
|
| Net Long Term Debt Issuance |
|
-3.04
-71205.04%
|
-0.00
-100.02%
|
19.77
+952.41%
|
-2.32
|
| Net Common Stock Issuance |
|
25.40
-57.91%
|
60.33
+100.95%
|
30.02
-51.81%
|
62.31
|
| Proceeds From Stock Option Exercised |
|
22.63
|
0.00
|
0.00
-100.00%
|
0.21
|
| Net Other Financing Charges |
|
—
|
—
|
-0.82
-37.32%
|
-0.60
|
| Changes In Cash |
|
-6.84
+19.14%
|
-8.46
-241.19%
|
6.00
+105.35%
|
2.92
|
| Beginning Cash Position |
|
14.93
-36.19%
|
23.39
+34.46%
|
17.40
+20.17%
|
14.48
|
| End Cash Position |
|
8.08
-45.85%
|
14.93
-36.19%
|
23.39
+34.46%
|
17.40
|
| Free Cash Flow |
|
-51.83
+24.66%
|
-68.79
-60.08%
|
-42.97
+24.18%
|
-56.67
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.47
-59.05%
|
1.16
-25.48%
|
1.56
|
| Change In Income Tax Payable |
|
-1.55
|
0.00
|
—
|
—
|
| Change In Tax Payable |
|
-1.55
|
0.00
|
—
|
—
|
| Common Stock Issuance |
|
25.40
-57.91%
|
60.33
+100.95%
|
30.02
-51.81%
|
62.31
|
| Earnings Losses From Equity Investments |
|
0.14
+39.97%
|
0.10
+816.00%
|
0.01
-77.43%
|
0.05
|
| Issuance Of Capital Stock |
|
25.40
-57.91%
|
60.33
+100.95%
|
30.02
-51.81%
|
62.31
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-06-03 View
- 42026-06-01 View
- 8-K2026-06-01 View
- 8-K2026-05-29 View
- 8-K2026-05-28 View
- 42026-05-27 View
- 42026-05-27 View
- 42026-05-27 View
- 42026-05-27 View
- 8-K2026-05-26 View
- 8-K2026-05-18 View
- 10-Q2026-05-15 View
- 8-K2026-05-13 View
- 8-K2026-04-23 View
- 8-K2026-04-21 View
- 8-K2026-04-07 View
- 8-K2026-03-25 View
- 8-K2026-03-16 View
- 8-K2026-03-11 View
- 8-K2026-03-10 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|